RhumbLine Advisers’s Annovis Bio ANVS Stock Holding History

RhumbLine Advisers’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-350	Closed	-$780	–	4138
2026 Q1	$780	Hold	350	–	–	﹤0.01%	3998
2025 Q4	$1.21K	Hold	350	–	–	﹤0.01%	4022
2025 Q3	$724	Hold	350	–	–	﹤0.01%	4041
2025 Q2	$759	Hold	350	–	–	﹤0.01%	4055
2025 Q1	$525	Hold	350	–	–	﹤0.01%	4054
2024 Q4	$1.76K	Hold	350	–	–	﹤0.01%	4044
2024 Q3	$2.82K	Buy	+350	New	+$3.28K	﹤0.01%	4040

Other funds holding ANVS

EAM

Empery Asset Management New York $86.5M AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Tudor Investment Corp Stamford, Connecticut $71.9B AUM 42.37% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

RhumbLine Advisers's ANVS Position: Q2 2026 in Review

RhumbLine Advisers sold out of Annovis Bio (ANVS) in Q2 2026, closing a stake of 350 shares — an estimated $780 sold.

RhumbLine Advisers first reported a position in ANVS in Q3 2024 and held it in 7 quarters. The position peaked at $2.82K in Q3 2024. 61 funds tracked by Wall St. Rank hold ANVS as of Q2 2026.

RhumbLine Advisers reported no remaining Annovis Bio position as of Q2 2026 after selling out during the quarter.
RhumbLine Advisers sold 350 Annovis Bio shares in Q2 2026, an estimated $780.
RhumbLine Advisers first reported a position in Annovis Bio in Q3 2024 and held it in 7 quarters.
RhumbLine Advisers's Annovis Bio position peaked at $2.82K in Q3 2024.
61 funds tracked by Wall St. Rank held Annovis Bio as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.